Best practice recommendations for the diagnosis and management of hypoparathyroidism

作者：Aliya Khan, Dalal S. Ali, John P. Bilezikian, Sigríður Björnsdóttir, Michael T. Collins, Natalie E. Cusano, Peter R. Ebeling, Ghada El‐Hajj Fuleihan, Seiji Fukumoto, Andrea Giustina, Stéphanie Kaiser, Christian A. Koch, Tayyab Khan, Patty Keating, Jianmin Liu, Christos S. Mantzoros, Michael Mannstadt, Ambrish Mithal, Nancy D. Perrier, Michele Rayes, René Rizzoli, Yumie Rhee, Mishaela R. Rubin, Kelly L. Roszko, Muhammad Shrayyef, Dolores Shoback, Tanja Sikjær, Heide Siggelkow, Jad Sfeir, Rajesh V. Thakker, Stan Van Uum, Karen K. Winer, Dilek Gogaş Yavuz, Bülent Okan Yıldız, Hajar Abu Alrob, Maria Luisa Brandi · 发表于：Metabolism · 年份：2025 · DOI：10.1016/j.metabol.2025.156335 · 被引用次数：18 · 研究领域：Parathyroid Disorders and Treatments、Thyroid and Parathyroid Surgery、Genetic Syndromes and Imprinting

BACKGROUND: Hypoparathyroidism (HypoPT) is characterized by low serum calcium due to insufficient parathyroid hormone (PTH). This manuscript builds upon the 2022 international HypoPT guidelines and three systematic reviews, which have been further informed by updated narrative reviews and expert consensus. This paper presents current best practice consensus recommendations for the diagnosis and management of HypoPT. METHODS: An International Panel of Experts updated the previous systematic reviews (SR's), conducted narrative reviews, developed, and subsequently approved these best practice recommendations at the Parathyroid Summit, held as a pre-Endocrine Society meeting in May 2024 (Boston, USA). RESULTS: Diagnostic criteria for chronic HypoPT require hypocalcemia with inappropriately normal or low PTH levels. Conventional therapy is recommended as first line therapy and includes calcium supplementation, active vitamin D, correction of vitamin D inadequacy and correction of abnormalities in serum magnesium. Monitoring is required to achieve optimal serum calcium while avoiding hyperphosphatemia, hypercalciuria and declines in renal function. Assessment of HypoPT complications is required including skeletal health assessment in postmenopausal women and men over the age of 50 years. Specific strategies are provided for managing HypoPT during pregnancy and lactation as well as in children. PTH replacement with palopegteriparatide has been approved and is an important therapeuti...